文献速递认知障碍与痴呆

阿尔茨海默病生物标志物在高龄老人中的临床影响与预后价值

Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old.
PubMed 文献 · Neurology · 2026-06-17

本研究为SPIN队列的回顾性纵向研究,纳入167例≥80岁轻度认知障碍患者,评估脑脊液AD生物学与血浆p-Tau217的临床影响及预后价值。结果显示AD生物学组基线认知更差且MMSE下降更快,血浆p-Tau217对AD生物学诊断准确率高,并可预测痴呆转化风险。

要点

  • 高龄MCI患者中AD生物学阳性者基线记忆更差且认知下降更快。
  • 血浆p-Tau217诊断AD生物学准确率高,可辅助识别高危患者。
  • 血浆p-Tau217较高与痴呆转化风险增加相关。

核心结论

  • 在高龄MCI患者中,脑脊液AD生物学和血浆p-Tau217可识别认知下降更快及进展为痴呆风险更高的个体。

主要发现

  • AD生物学阳性者(n=116,69%)基线认知表现更差,尤其记忆(Cohen d=0.34,p=0.03)。
  • AD生物学阳性者MMSE年下降更快(-0.47 vs -0.18分/年,p<0.01)。
  • 血浆p-Tau217浓度较高者进展为痴呆的风险增加(HR 1.49,95%CI 1.05-2.13,p=0.026)。

关键数值与推荐

  • AD生物学以脑脊液p-Tau181/Aβ42比值定义。
  • 血浆p-Tau217诊断AD生物学AUC 0.93(95%CI 0.88-0.98),切点0.19 pg/mL,灵敏度94.5%,特异度84%。

临床怎么用

  • 对高龄MCI患者可检测血浆p-Tau217辅助判断AD生物学及预后风险。
  • AD生物学阳性或血浆p-Tau217较高者应加强认知随访和痴呆转化监测。

局限性

  • 单中心设计。
  • 样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Alzheimer disease (AD) is increasingly viewed as a clinical-biological continuum, but the utility of biomarkers in individuals aged ≥80 years, the so-called "very old," remains uncertain, because of concerns about its clinical usefulness. This study aimed to determine the clinical impact and prognostic value of AD biomarkers in very old individuals. METHODS: We performed a retrospective longitudinal cohort study within the Sant Pau Initiative on Neurodegeneration (SPIN, Barcelona, Spain), a memory clinic-based research cohort. Patients were referred from primary care physicians or community neurologists for evaluation within a public universal health care catchment area. We included SPIN participants evaluated between October 2013 and May 2024 who were aged ≥80 years and had mild cognitive impairment (MCI) at the baseline visit. Participants underwent standardized clinical and neuropsychological assessments and had CSF and plasma biomarker measurements available. AD biology was defined by the CSF phosphorylated tau at threonine 181/amyloid-β 42 ratio. Plasma phosphorylated tau at threonine 217 (p-Tau217) was evaluated for (1) diagnostic accuracy for AD biology and (2) prognostic associations with longitudinal cognitive change (Mini-Mental State Examination [MMSE]) and progression to dementia. Analyses used linear mixed-effects models for MMSE trajectories and Cox regression for dementia conversion. RESULTS: A total of 167 participants were included (mean age 82.3 years, 59% women) with a mean follow-up of 35.8 months; the ones with AD biology (n = 116, 69%) had worse baseline cognitive performance, particularly in memory, compared with those without (Cohen d = 0.34, p = 0.03). Plasma p-Tau217 showed excellent diagnostic accuracy for detecting AD biology (0.93, 95% CI 0.88-0.98; cutoff 0.19 pg/mL; sensitivity 94.5%; specificity 84%). Over time, participants with AD biology declined faster on the MMSE than those without (-0.47 vs -0.18 points per year; p < 0.01). Cox models showed an increased risk of progression to a dementia stage among individuals with higher plasma p-Tau217 concentrations (hazard ratio 1.49, 95% CI 1.05-2.13, p = 0.026). DISCUSSION: In very old individuals with MCI, AD biology (CSF) and plasma p-Tau217 identify individuals at higher risk of faster cognitive decline and progression to dementia. Limitations of this study include the single-center design and the modest sample size.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ceriello C, Torres OH, Rubio-Guerra S, et al. Clinical Impact and Prognostic Value of Alzheimer Disease Biomarkers in the Very Old. Neurology. 2026. PMID: 42308436. doi:10.1212/WNL.0000000000218180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。